Evaluation of the effects of erythro-9(2-hydroxy-3-nonyl) adenine (EHNA) on HIV-1 production in vitro.
Effects of erythro-9(2-hydroxy-3-nonyl) adenine (EHNA), an inhibitor of the common Adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4.), on HIV-1 production was evaluated in vitro. Reverse transcriptase (RT) activity in the supernatant was inhibited by nearly 50% in EHNA-treated HIV-1 infected H9 cells, when compared with untreated but infected H9 cells. There was also a significant decrease in cell viability, but this was reversed following the addition of deoxycytidine (dC) to these cultures. The combined treatment was also effective in suppressing HIV-1 release from HIV-1-infected U937 cells. This combined EHNA plus dC treatment had no effect on RT activity in the cell lysates, suggesting that the inhibition of HIV-1 production may be due to the disturbance of virus release from infected cells.
Sei
Y
Y
Laboratory of Neuroscience, NIDDK, Bethesda, MD 20892.
Inoue
M
M
Tsuboi
I
I
Yokoyama
M M
MM
Arora
P K
PK
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D058892:Adenosine Deaminase Inhibitors; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D003841:Deoxycytidine / Q000494:pharmacology; D004357:Drug Synergism; D005434:Flow Cytometry; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D012194:RNA-Directed DNA Polymerase / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects*
D058892:Adenosine Deaminase Inhibitors; D000998:Antiviral Agents; D015699:HIV Envelope Protein gp120; D003841:Deoxycytidine; C010192:9-(2-hydroxy-3-nonyl)adenine; D012194:RNA-Directed DNA Polymerase; D000225:Adenine